Want to see GB:SAR full AI Analyst Report?

Sareum Holdings (SAR) Price & Analysis

26 Followers

SAR Stock Chart & Stats

22.00 p

0.00 p(0.00%)

At close: Jul 27 4:00 PM EDT

22.00 p

0.00 p(0.00%)

Day’s Range― - ―

52-Week Range9.50 p - 29.00 p

Previous CloseN/A

Volume96.80K

Average Volume (3M)619.72K

Market Cap

£31.87M

Enterprise Value28.00M

Total Cash (Recent Filing)£2.49M

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta-0.15

Next Earnings

Oct 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding138,565,170

10 Day Avg. Volume1,134,615

30 Day Avg. Volume619,716

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)8.68

Price to Sales (P/S)0.00

P/FCF Ratio-7.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clean Balance Sheet — No Reported DebtA debt-free balance sheet materially reduces solvency and refinancing risk for an early-stage biotech. Without fixed interest burdens the company can direct limited capital to R&D and licensing efforts, extending runway and preserving strategic optionality during long development cycles.

Partnering/licensing-focused Business ModelA partnership/licensing model aligns with capital efficiency for small biotechs: value is realized through discrete deal milestones rather than commercial infrastructure. This structural model lets Sareum monetize assets via large pharma partners, reducing long-term commercialization risk and capex needs.

Focused R&D In TYK2/JAK Kinase PathwaysA concentrated scientific focus builds durable technical expertise and a coherent pipeline strategy. Specialization in TYK2/JAK small-molecule inhibitors targets validated biology with broad addressable markets in autoimmune/inflammatory diseases, improving the odds of attractive partner interest and licensing outcomes.

Bears Say

Pre-revenue With Persistent Operating LossesSustained operating losses mean the company cannot self-fund development and lacks commercial cash inflows. Over multiple periods this drains equity, forces dilution or costly financing, and increases execution risk if partners or capital are delayed, making long-term program progression contingent on external funding.

Significant Cash Burn; Negative Free Cash FlowPersistent negative operating and free cash flow require repeated financing and constrain strategic flexibility. Even with recent narrowing, ongoing burn drives dependency on capital markets or partners, elevating dilution risk and potentially forcing prioritization or shelving of programs if funding conditions tighten.

High Dependence On Partnerships And Limited Internal ResourcesRelying on external deals creates binary, milestone-driven outcomes; combined with small equity and a five-person team, Sareum may lack capacity and balance-sheet heft to advance multiple programs independently. This concentration amplifies execution and timing risk for durable growth.

Sareum Holdings News

Sareum Completes Key Toxicology Milestone for Autoimmune Drug Candidate SDC-1801

Sareum Holdings ( ($GB:SAR) ) has shared an update. Sareum Holdings has completed dosing in its Phase 2-enabling...

13d ago

Sareum’s SDC-1801 Phase 1 Data Published, Paving Way for Phase 2-Ready Package

An update from Sareum Holdings ( ($GB:SAR) ) is now available. Sareum Holdings has published the full Phase...

1M ago

Sareum Adds £62,500 via Warrant Exercise as Share Count Rises

Sareum Holdings ( ($GB:SAR) ) has issued an update. Sareum Holdings has received notice for the exercise of...

3M ago

Sareum Restarts Key Toxicology Study as TYK2 Pipeline and Partnering Drive Half-Year Progress

The latest announcement is out from Sareum Holdings ( ($GB:SAR) ). Sareum Holdings reported half-year results to 31...

5M ago

Sareum to Release Interim Results and Host Live Investor Presentation

Sareum Holdings ( ($GB:SAR) ) has issued an update. Sareum Holdings said it will publish its unaudited interim...

5M ago

Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings has restarted its Phase 2-enabling toxicology programme...

6M ago

Sareum Holdings Passes All Resolutions at AGM, Strengthening Governance

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings plc announced that all resolutions at its...

8M ago

Sareum Holdings Advances Pipeline and Strengthens Portfolio

Sareum Holdings ( ($GB:SAR) ) has shared an update. Sareum Holdings has made significant progress in its pipeline,...

8M ago

Sareum Holdings Announces AGM and Releases Annual Report

Sareum Holdings ( ($GB:SAR) ) has provided an update. Sareum Holdings PLC has announced its Annual General Meeting...

9M ago

Sareum Holdings Enhances Financial Advisory Team with New Joint Broker Appointment

The latest announcement is out from Sareum Holdings ( ($GB:SAR) ). Sareum Holdings PLC has appointed Singer Capital...

9M ago

SAR FAQ

What was Sareum Holdings PLC’s price range in the past 12 months?

Sareum Holdings PLC lowest share price was 9.50 p and its highest was 29.00 p in the past 12 months.

What is Sareum Holdings PLC’s market cap?

Sareum Holdings PLC’s market cap is £31.87M.

When is Sareum Holdings PLC’s upcoming earnings report date?

Sareum Holdings PLC’s upcoming earnings report date is Oct 26, 2026 which is in 85 days.

How were Sareum Holdings PLC’s earnings last quarter?

Sareum Holdings PLC released its earnings results on Mar 12, 2026. The company reported -0.012 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.012 p.

Is Sareum Holdings PLC overvalued?

According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sareum Holdings PLC pay dividends?

Sareum Holdings PLC does not currently pay dividends.

What is Sareum Holdings PLC’s EPS estimate?

Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sareum Holdings PLC have?

Sareum Holdings PLC has 138,565,170 shares outstanding.

What happened to Sareum Holdings PLC’s price movement after its last earnings report?

Sareum Holdings PLC reported an EPS of -0.012 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.

Which hedge fund is a major shareholder of Sareum Holdings PLC?

Currently, no hedge funds are holding shares in GB:SAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sareum Holdings PLC

Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform. Its development portfolio currently features programs targeting Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. Sareum has also forged strategic partnerships with the Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. Founded in 2003, the company is headquartered in Cambridge, United Kingdom.